For years, every GLP-1 approved for weight loss was a weekly or daily injection. That changed in the last twelve months. The FDA approved the Wegovy pill (oral semaglutide 25 mg) on December 22, 2025, and Foundayo (orforglipron) on April 1, 2026. Both are once-daily tablets for adults with obesity, or adults with overweight plus at least one weight-related health condition, used alongside a reduced-calorie diet and more physical activity.
They are not the same drug, and the practical differences matter. Here’s a side-by-side look using the FDA, manufacturer, and trial sources listed at the end. For dosing steps and label details, see our orforglipron (Foundayo) medication page and oral vs. injectable semaglutide comparison.
The quick comparison
| Foundayo | Wegovy pill | |
|---|---|---|
| Active ingredient | Orforglipron (small-molecule GLP-1 receptor partial agonist) | Semaglutide (peptide GLP-1 receptor agonist) |
| Maker | Eli Lilly | Novo Nordisk |
| FDA approval | April 1, 2026 | December 22, 2025 |
| How often | Once daily | Once daily |
| Food and water rules | None; any time of day | First thing in the morning, empty stomach, no more than 4 oz of water |
| Key weight-loss trial | ATTAIN-1, 72 weeks | OASIS 4, 64 weeks |
| Self-pay price range (Nov 2026) | $149 to $299 a month | $149 to $299 a month |
| Extra labeled use | — | Reduces risk of major cardiovascular events in adults with overweight or obesity and established cardiovascular disease |
The biggest practical difference: how you take it
Semaglutide is a peptide, and peptides are hard to absorb through the gut. That’s why the Wegovy pill comes with strict rules: take it first thing in the morning on an empty stomach with no more than 4 ounces of water, as described in JAMA’s summary of the approvals. Follow the full timing instructions on your prescription label.
Orforglipron is a small molecule rather than a peptide. FDA says Foundayo “does not need to be taken on an empty stomach,” and Lilly says it can be taken any time of day without food or water restrictions. For people who take other morning medications or have unpredictable mornings, that’s a real difference.
What the trials showed
The two pills have not been tested against each other. Their main trials enrolled different people for different lengths of time, so the numbers below can’t be lined up as a contest.
Wegovy pill (OASIS 4). 307 adults with obesity or overweight plus a weight-related condition, without diabetes, over 64 weeks. Counting everyone who started, regardless of whether they stayed on treatment, average weight loss was about 13.6% on the 25 mg pill versus about 2.4% on placebo. Among people who stayed on treatment it was about 16.6% versus 2.7%.
Foundayo (ATTAIN-1). Over 72 weeks, people on the highest dose lost an average of 11.1% of body weight regardless of whether they finished the trial, versus 2.1% on placebo. Among those who stayed on treatment, it was 12.4% versus 0.9%, according to Lilly.
Why two numbers? Trials report results both for everyone randomized and for people who kept taking the drug. The first is closer to real-world results; the second shows what the drug can do when taken as directed.
Side effects and warnings
Both drugs work on the GLP-1 receptor, so the common side effects look familiar to anyone who has read about injectable GLP-1s.
- Foundayo: FDA lists nausea, constipation, diarrhea, vomiting, indigestion, stomach pain, headache, bloating, fatigue, burping, reflux, gas, and hair loss. Its label also has warnings and precautions for pancreatitis, severe gastrointestinal reactions, kidney injury from dehydration, low blood sugar, allergic reactions, diabetic retinopathy in people with type 2 diabetes, gallbladder disease, and aspiration during anesthesia or deep sedation. It carries a boxed warning for thyroid C-cell tumors and should not be combined with another GLP-1 receptor agonist.
- Wegovy pill: Novo Nordisk reports that the common adverse reactions in OASIS 4, including nausea, diarrhea, and vomiting, were similar to those seen with Wegovy injection 2.4 mg. Semaglutide products, including Wegovy, also carry a boxed warning for thyroid C-cell tumors.
For a plain-language rundown of GI side effects and how people manage them, see our side effects hub.
What each pill costs
Both companies sell the pills directly to cash-pay patients with a prescription. Prices below were read on the manufacturers’ pages in November 2026 and change often, so check the source before you rely on them.
Foundayo through LillyDirect (read November 21, 2026):
- 0.8 mg (starting dose): starting at $149 a month
- 2.5 mg: starting at $149 a month (temporarily reduced through December 31, 2026)
- 5.5 mg: starting at $199 a month (temporarily reduced through December 31, 2026)
- 14.5 mg and 17.2 mg: starting at $299 a month when refilled within 45 days
- 9 mg: see LillyDirect for the current price
Wegovy pill through Novo Nordisk’s self-pay offer (read November 20, 2026):
- 1.5 mg: $149 a month
- 4 mg: $199 a month
- 9 mg and 25 mg: $299 a month
With commercial insurance that covers the drug, both companies advertise savings programs that can bring the cost down to as little as $25 a month, with terms and caps. Eligible Medicare Part D patients may be able to get them through the Medicare GLP-1 Bridge for a $50 copay with prior authorization.
For every brand’s current self-pay and list prices in one place, see our GLP-1 pricing hub and Wegovy cost breakdown. If you’re working through coverage, our insurance guide covers prior authorization and appeals.
Who might lean toward which
These are questions to bring to a prescriber, not recommendations:
- If morning routines are hard to control, or you take other medications first thing, Foundayo’s lack of food and water rules may be easier to stick with.
- If you have established cardiovascular disease, note that the Wegovy pill’s label includes a cardiovascular risk-reduction indication.
- If you’re switching from an injection, don’t assume doses translate one-to-one. Lilly’s own FAQ says to work out the transition approach and dose with your doctor.
- If cost is the deciding factor, the self-pay ranges are similar today, but temporary Foundayo prices end December 31, 2026.
Finding a prescriber
Both pills need a prescription. You can get one from a primary care clinician, an obesity medicine specialist, or a telehealth service. Compare GLP-1 providers in our directory to see which clinics list oral GLP-1 options, their pricing, and how they handle follow-up care.
Last updated November 21, 2026. Prices and program terms change often; we re-check them against the manufacturer pages above.
